clinical trial · NCT00092066
A Study to Evaluate the Safety, Tolerability, and Efficacy of an Investigational Drug and Dietary Supplement in Men and Postmenopausal Women With Osteoporosis (0217A-227)
Organon and Co·phase3·completed·n = 717
OsteoporosisVitamin D DeficiencyMK0217A, alendronate sodium (+) cholecalciferol / Duration of Treatment: 15 weeks
brief summary
The purpose of this study is to test the safety, tolerability and effectiveness of an investigational drug and dietary supplement to reduce the risk of vitamin D insufficiency and deficiency during the treatment of osteoporosis in men and postmenopausal women.
started
Sep 24, 2003
primary completion
May 1, 2004
completion
May 1, 2004
last updated
Aug 14, 2024
official title
A 15-Week, Double-Blind, Randomized, Active-Controlled, Multi-Center Study With 24-Week Extension to Evaluate the Safety, Tolerability, Efficacy of Alendronate 70 mg Plus Vitamin D3 2800 IU Combination Tablet in Men and Postmenopausal Women With Osteoporosis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol